UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease
Condition: COVID-19 Infection Intervention: Drug: ursodeoxycholic acid Sponsor: Beijing Ditan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Autoimmune Disease | COVID-19 | Hospitals | Liver | Liver Disease | Research | Urology & Nephrology